gabapentin has been researched along with a 803467 in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Atkinson, R; Carroll, W; Chapman, M; Chu, K; Drizin, I; Faltynek, CR; Gauvin, D; Gregg, R; Gross, M; Hakeem, A; Hernandez, G; Honore, P; Jarvis, MF; Johnson, M; Joshi, S; Kort, M; Krafte, DS; Krambis, M; Liu, D; Liu, Y; Marron, B; Marsh, K; Matulenko, M; McGaraughty, S; Mikusa, JP; Pai, M; Roeloffs, R; Scanio, M; Shi, L; Shieh, CC; Sullivan, JP; Thomas, J; Wade, C; Wagoner, PK; Zhang, XF; Zhong, C; Zhu, C | 1 |
1 other study(ies) available for gabapentin and a 803467
Article | Year |
---|---|
A-803467, a potent and selective Nav1.8 sodium channel blocker, attenuates neuropathic and inflammatory pain in the rat.
Topics: Action Potentials; Analgesics; Aniline Compounds; Animals; Capsaicin; Evoked Potentials; Furans; Ganglia, Spinal; Humans; Inflammation; Kinetics; Male; Mononeuropathies; NAV1.8 Voltage-Gated Sodium Channel; Nerve Tissue Proteins; Neurons; Pain; Pain Management; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Sodium Channel Blockers; Sodium Channels | 2007 |